DSD. Sène

D. Sène

*This is an algorithmically generated author record based on publicly available information.

D. Sène has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Patrice Cacoub

    Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France

    4 shared publications
  • A L Boch

    1 shared publication
  • A Rousseau

    1 shared publication
  • Benjamin Terrier

    Service de Médecine Interne, Hôpital Cochin, Paris, France

    1 shared publication
  • D. Messous

    1 shared publication
  • David Saadoun

    Sorbonne Universités AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et Immunologie Clinique, F-75013, Centre National de Référence Maladies Autoimmunes Systémiques Rares, Centre National de Référence Maladies Autoinflammatoires et Amylose Inflammatoire (CEREMAIA), Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), CIC Biotherapy, INSERM 959, Groupe Hospitalier Pitié-Salpetriere, AP-HP, Paris, France

    1 shared publication

Latest Publications

  • Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus‐infected patients treated with pegylated interferon plus ribavirin and rituximab

    by G. Geri, B. Terrier, F. Imbert‐Bismut, D. Saadoun, D. Sène, T. Poynard, P. Cacoub

    Summary. Therapeutic options in hepatitis C virus (HCV)‐related vasculitis may target the viral trigger using antiviral therapy [pegylated interferon plus ribavirin (PEG‐IFN/RBV)], and/or the downstream B‐cell arm of autoimmunity with rituximab (RTX). To date, no study has compared the efficacy of RTX combined with PEG‐IFN/RBV on biomarkers of liver insufficiency in patients with severe liver fibrosis. Twenty‐eight untreated HCV‐related vasculitis patients with severe liver fibrosis (Metavir F3–F4) were included: 14 patients received RTX plus PEG‐IFN/RBV and 14 patients PEG‐IFN/RBV. The main clinical and biological data were recorded and compared at baseline, month 3 (M3), M12 and M24 of follow‐up. Baseline epidemiological, clinical, virological and immunological features were similar between the groups. The virological response did not differ between cases and controls. The alanine aminotransferase (ALT) level and HCV viral load did not increase in patients treated with RTX. Serum albumin levels increased in patients treated with RTX at M3 and M6 (108% and 111% of baseline value; P = 0.06 and P = 0.13), whereas it was stable in patients treated without RTX. FibroTest values decreased from 0.70 at baseline to 0.59 at M3 (P = 0.5) and returned to 0.69 at M24 in the RTX‐PEG‐IFN/RBV group, whereas they were stable in the PEG‐IFN/RBV group. RTX is safe in patients with severe HCV liver fibrosis and vasculitis. No beneficial effects of RTX were evidenced on liver fibrosis progression, but we found interesting correlations with the serum albumin level, FibroTest values and B‐cell count.


    • 1 October 2009
      • Vol. 28  (5) , 387-94

    Primary pineal melanoma with leptomeningeal spreading: case report and review of the literature.

    by G Martin-Blondel, A Rousseau, A L Boch, P Cacoub, D Sène

    Primary melanomas of the pineal region are exceedingly rare and may be difficult to diagnose. Clinical, radiological and pathological features as well as diagnostic procedures are discussed. CASE HISTORY We report herein on a 44-year-old man who presented with uncontrolled epileptic seizures. Magnetic resonance imaging revealed a pineal mass hyperintense on T1-weighted and isointense on T2-weighted sequences with diffuse leptomeningeal involvement and intense homogeneous contrast enhancement after gadolinium administration. A frontal leptomeningeal and cortical biopsy was performed. Histological examination showed a malignant melanocytic tumor cell proliferation expressing Melan-A, but not HMB-45 or S100 protein. Even if we have no proof that the tumor actually arose in the pineal gland, based on the radiological and histological findings, and on the unremarkable dermatologic and ophthalmologic examinations, a primary pineal melanoma with leptomeningeal dissemination was diagnosed. The patient received temozolomide-based chemotherapy followed by whole brain irradiation. The patient died 52 weeks after disease onset and 13 weeks after treatment initiation. A diagnosis of pineal melanoma should be considered in the presence of a pineal mass that appears hyperintense on T1-weighted images and hypo- to isointense on T2-weighted images. The diagnosis is provided by pathological examination of tumor specimens obtained at surgical resection or at leptomeningeal biopsy. However, immunochemistry using anti-Melan-A, -S100 protein and/or -HMB45 antibodies on cerebrospinal fluid and leptomeningeal samples may be helpful in diagnosing such a disease. The prognosis of primary pineal melanoma is variable but meningeal spreading carries a dismal prognosis. The best therapeutic management is yet to be defined.


  • P.365 Biochemical markers of liver fibrosis and activity in patients with chronic hepatitis C and mixed cryoglobulinemia systemic vasculitis

    by D. Sène, N. Limal, D. Messous, P. Ghillani-Dalbin, F. Charlotte, J. Piette, F. Imbert-Bismut, P. Halfon, T. Poynard, P. Cacoub